GLP-1 Pill Cuts Heavy Drinking Days in New Study

Scientists just found promising evidence that a pill many people take for weight loss might also help those struggling with alcohol addiction reduce their heavy drinking days.

Researchers at the University of Colorado Anschutz tested oral semaglutide on 50 people diagnosed with moderate to severe alcohol use disorder. Half took the medication daily for eight weeks while the others received a placebo.

The results brought genuine hope. People taking semaglutide reported fewer days of heavy drinking compared to those on the placebo. They also consumed less alcohol on the days when they did drink and experienced fewer negative consequences from their alcohol use.

Lead researcher Joseph Schacht says semaglutide's effects appear larger than other FDA-approved medications currently used to treat alcohol use disorder. That matters for millions of Americans searching for effective treatment options.

The trial used relatively low doses of the medication, low enough that participants didn't lose any weight during the study. This suggests the drug could help people with alcohol use disorder even if they don't need to lose weight.

Interestingly, trial participants also reported using less cannabis during the study. This unexpected finding hints that GLP-1 medications might help with multiple types of substance use, not just alcohol.

Why This Inspires

For years, treatment options for alcohol use disorder have been limited and often ineffective. This research opens a door to potentially more powerful tools that could help people moderate their drinking, even if they can't quit entirely.

The harm reduction approach matters too. Not everyone with alcohol use disorder can or will stop drinking completely, but reducing heavy drinking days can dramatically improve health outcomes and quality of life.

Larger trials are already underway to confirm these findings and explore whether higher doses might work even better. Researchers also want to understand if the benefits continue after people stop taking the medication.

If bigger studies confirm these early results, doctors may soon have a powerful new option to offer patients struggling with alcohol addiction. That possibility represents real progress for a condition that affects roughly 29 million American adults.

The pill form also offers convenience that injectable versions don't, potentially making treatment more accessible to people who need it most.